BERLIN — New data from two new studies suggest that for patients with multiple sclerosis (MS) for whom treatment with natalizumab (Tysabri, Biogen) or fingolimod (Gileyna, Novartis) fails, switching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results